# Myanmar

## Population 2018

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>181 (119–256)</td>
<td>338 (222–477)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>15 (10–22)</td>
<td>29 (19–41)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>11 (7.4–16)</td>
<td>21 (14–30)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>21 (12–31)</td>
<td>39 (23–58)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>3.7 (2.5–5.2)</td>
<td>6.9 (4.6–9.7)</td>
</tr>
</tbody>
</table>

## Tuberculosis profile

### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 4.9% (4.7–5.1)%
- Previously treated cases: 20% (19–21)%

### TB case notifications, 2018

- % tested with rapid diagnostics at time of diagnosis: 42%
- % with known HIV status: 89%
- % pulmonary: 91%
- % bacteriologically confirmed: 44%
- % children aged 0–14 years: 19%
- % women: 29%
- % men: 52%

### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 76% (54–120)%
- TB patients facing catastrophic total costs, 2015: 60% (56–63)%
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 14% (8–22)%

### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 92%
- New cases: 92%
- Previously treated cases: 84%

### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2017</td>
<td>87%</td>
<td>126 746</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2017</td>
<td>78%</td>
<td>1638</td>
</tr>
<tr>
<td>HIV-positive TB cases registered in 2017</td>
<td>73%</td>
<td>10 294</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2016</td>
<td>79%</td>
<td>2 612</td>
</tr>
</tbody>
</table>

### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 15%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 3.1% (2.8–3.4)

### TB financing, 2019

- National TB budget (US$ millions): 62

---

*Ranges represent uncertainty intervals

MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

MDR/RR-TB: MDR-resistant TB, XDR-TB: extensively drug-resistant TB

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-01-22

Data: www.who.int/tb/data